Lilly to Acquire Merida for Autoantibody Degradation
Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash, including an undisclosed upfront payment and contingent milestones. Merida is developing engineered biologics intended to remove disease-causing autoantibodies selectively while…
